Blueprint Medicines Corp (NASDAQ:BPMC) price on current trading day, rose 0.07% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $128.29.
A look at the stock’s price movement, the level at last check in today’s session was $128.2, moving within a range at $128.2 and $128.32. The beta value (5-Year monthly) was 0.833. Turning to its 52-week performance, $128.52 and $73.04 were the 52-week high and 52-week low respectively. Overall, BPMC moved 0.54% over the past month.
Blueprint Medicines Corp’s market cap currently stands at around $8.30 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-01.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BPMC is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
10 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 6 recommend BPMC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BPMC’s current price about 0.12% and 14.98% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 74.47, while 7-day volatility ratio is 0.20% and 0.26% in the 30-day chart. Further, Blueprint Medicines Corp (BPMC) has a beta value of 0.94. Analysts have given the company’s stock an average 52-week price target of $141, forecast between a low of $132 and high of $150. Looking at the price targets, the low is -2.89% off recent price level in today’s trading while to achieve the yearly target high, it has to move -16.92%. Nonetheless, investors will most likely welcome a -9.91% jump to $141 which is the analysts’ median price.
If we refocus on Blueprint Medicines Corp (NASDAQ:BPMC), historical trading data shows that trading volumes averaged 3.01 over the past 10 days and 2.97 million over the past 3 months. The company’s latest data on shares outstanding shows there are 64.56 million shares.
The 3.71% of Blueprint Medicines Corp’s shares are in the hands of company insiders while institutional holders own 106.61% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.13 million on 2025-06-13, giving us a short ratio of 0.62. The data shows that as of 2025-06-13 short interest in Blueprint Medicines Corp (BPMC) stood at 545.0 of shares outstanding, with shares short falling to 5.67 million registered in 2025-05-15. Current price change has pushed the stock 17.50% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BPMC stock continues to rise going into the next quarter.
